(Reuters) - South Korea's Celltrion Healthcare has launched a copycat version to AbbVie Inc's Humira at about a 5% discount, adding to the growing com.
Experts assess the potential of colchicine 0.5 mg to treat residual risk for atherosclerotic cardiovascular disease (ASCVD) in patients with immune-mediated inflammatory diseases (IMIDs).
during the forecast period. Factors such as regulatory approvals, favorable reimbursement policies, rising demand for cost effective biosimilars is driving.
Roundup: Coherus Resolves AbbVie Dispute; Bio-Thera Solutions and Celltrion Expand Respective Partnerships centerforbiosimilars.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from centerforbiosimilars.com Daily Mail and Mail on Sunday newspapers.